Loading...
XTAENXGN
Market cap1mUSD
Dec 20, Last price  
65.70ILS
1D
2.50%
1Q
-4.23%
Jan 2017
-42.97%
Name

Nextgen Biomed Ltd

Chart & Performance

D1W1MN
XTAE:NXGN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-24.18%
Rev. gr., 5y
%
Revenues
0k
Net income
-14m
L+65.56%
-8,217,000-4,930,000-4,325,000-1,807,000-1,499,000-1,264,000-1,214,000-1,296,000-2,550,000-8,572,000-14,192,000
CFO
-4m
L+60.01%
-1,205,000-3,273,000-4,012,000-1,513,000-1,661,000-1,241,000-1,146,000-1,537,000-2,658,000-2,753,000-4,405,000

Profile

Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.
URL
https://www.nextgen-biomed.com
IPO date
Dec 06, 1999
Employees
15
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
5,248
2,493
2,837
Unusual Expense (Income)
NOPBT
(5,248)
(2,493)
(2,837)
NOPBT Margin
Operating Taxes
799
305
Tax Rate
NOPAT
(5,248)
(3,292)
(3,142)
Net income
(14,192)
65.56%
(8,572)
236.16%
(2,550)
96.76%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,446
BB yield
-3.45%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
1,379
2,138
Net debt
(145)
(5,240)
(11,960)
Cash flow
Cash from operating activities
(4,405)
(2,753)
(2,658)
CAPEX
(33)
(500)
Cash from investing activities
(786)
(4,000)
(2,500)
Cash from financing activities
11,446
FCF
(4,269)
(3,285)
(3,138)
Balance
Cash
145
5,240
11,960
Long term investments
Excess cash
145
5,240
11,960
Stockholders' equity
(66,169)
(51,969)
(43,389)
Invested Capital
65,190
65,598
66,233
ROIC
ROCE
536.06%
EV
Common stock shares outstanding
7,263
43,349
39,676
Price
1.27
-66.19%
3.76
-55.05%
8.37
-41.88%
Market cap
9,239
-94.33%
163,077
-50.89%
332,092
-29.08%
EV
8,975
157,726
320,029
EBITDA
(5,246)
(2,486)
(2,833)
EV/EBITDA
Interest
64
22
Interest/NOPBT